Highland Capital Management LLC Sells 200 Shares of Eli Lilly and Company (NYSE:LLY)

Highland Capital Management LLC decreased its holdings in shares of Eli Lilly and Company (NYSE:LLYGet Rating) by 1.8% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 10,869 shares of the company’s stock after selling 200 shares during the quarter. Highland Capital Management LLC’s holdings in Eli Lilly and were worth $3,524,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in the business. McLean Asset Management Corp boosted its stake in Eli Lilly and by 2.4% during the 1st quarter. McLean Asset Management Corp now owns 1,405 shares of the company’s stock valued at $402,000 after purchasing an additional 33 shares during the period. RB Capital Management LLC boosted its stake in Eli Lilly and by 1.4% during the 2nd quarter. RB Capital Management LLC now owns 2,382 shares of the company’s stock valued at $772,000 after purchasing an additional 33 shares during the period. Woodstock Corp boosted its stake in Eli Lilly and by 0.6% during the 2nd quarter. Woodstock Corp now owns 5,585 shares of the company’s stock valued at $1,811,000 after purchasing an additional 34 shares during the period. Affiance Financial LLC boosted its stake in Eli Lilly and by 1.9% during the 1st quarter. Affiance Financial LLC now owns 1,835 shares of the company’s stock valued at $525,000 after purchasing an additional 35 shares during the period. Finally, Ashfield Capital Partners LLC boosted its stake in Eli Lilly and by 0.5% during the 1st quarter. Ashfield Capital Partners LLC now owns 7,975 shares of the company’s stock valued at $2,284,000 after purchasing an additional 36 shares during the period. Institutional investors own 82.45% of the company’s stock.

Insiders Place Their Bets

In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 89,458 shares of Eli Lilly and stock in a transaction dated Thursday, July 28th. The stock was sold at an average price of $332.85, for a total transaction of $29,776,095.30. Following the transaction, the insider now directly owns 103,875,441 shares in the company, valued at $34,574,940,536.85. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 89,458 shares of Eli Lilly and stock in a transaction dated Thursday, July 28th. The stock was sold at an average price of $332.85, for a total value of $29,776,095.30. Following the sale, the insider now owns 103,875,441 shares of the company’s stock, valued at approximately $34,574,940,536.85. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Jackson P. Tai purchased 656 shares of the company’s stock in a transaction on Friday, August 12th. The stock was purchased at an average cost of $304.19 per share, for a total transaction of $199,548.64. Following the purchase, the director now directly owns 62,857 shares in the company, valued at $19,120,470.83. The disclosure for this purchase can be found here. Over the last ninety days, insiders have sold 328,125 shares of company stock worth $108,581,151. Corporate insiders own 0.12% of the company’s stock.

Analyst Ratings Changes

A number of analysts have commented on LLY shares. Barclays raised their price objective on Eli Lilly and from $333.00 to $355.00 and gave the stock an “overweight” rating in a research report on Thursday, July 7th. Citigroup raised their price objective on Eli Lilly and from $285.00 to $370.00 in a research report on Thursday, August 25th. Morgan Stanley raised their price objective on Eli Lilly and from $395.00 to $412.00 and gave the stock an “overweight” rating in a research report on Wednesday, September 7th. UBS Group upgraded Eli Lilly and from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $335.00 to $363.00 in a research report on Thursday. Finally, BMO Capital Markets raised their price objective on Eli Lilly and from $369.00 to $396.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 6th. Three equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $332.19.

Eli Lilly and Trading Up 4.9 %

LLY stock opened at $310.87 on Friday. Eli Lilly and Company has a fifty-two week low of $220.20 and a fifty-two week high of $335.33. The company has a debt-to-equity ratio of 1.70, a current ratio of 1.10 and a quick ratio of 0.85. The stock has a market capitalization of $295.38 billion, a price-to-earnings ratio of 49.58, a P/E/G ratio of 1.92 and a beta of 0.38. The business has a fifty day moving average price of $314.33 and a 200 day moving average price of $304.45.

Eli Lilly and (NYSE:LLYGet Rating) last posted its earnings results on Thursday, August 4th. The company reported $1.25 earnings per share for the quarter, missing the consensus estimate of $1.86 by ($0.61). The business had revenue of $6.49 billion for the quarter, compared to the consensus estimate of $6.85 billion. Eli Lilly and had a return on equity of 85.58% and a net margin of 19.58%. The business’s revenue was down 3.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.87 earnings per share. Analysts expect that Eli Lilly and Company will post 7.97 EPS for the current fiscal year.

Eli Lilly and Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, September 9th. Shareholders of record on Monday, August 15th were issued a dividend of $0.98 per share. The ex-dividend date of this dividend was Friday, August 12th. This represents a $3.92 annualized dividend and a yield of 1.26%. Eli Lilly and’s dividend payout ratio is presently 62.52%.

Eli Lilly and Company Profile

(Get Rating)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.

Further Reading

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.